Entera Bio Ltd. (ENTX) · Oct 27, 2026 · Exec change
Board appointment — 20+ years of global clinical development experience
Entera Bio’s board appointment adds late-stage development and regulatory expertise as the company prepares EB613 for Phase 3.
Entera is a clinical-stage biotech moving its lead osteoporosis drug, EB613, toward a Phase 3 registrational program while advancing EB612 toward an initial clinical study; recent financing was intended to fund that plan into 2030. The appointment adds relevant execution experience at the right point in the pipeline. Juan Camilo Arjona Ferreira joins the board effective December 1, 2026, replacing Haya Taitel. His background spans late-stage development, regulatory affairs, women’s health and senior pharmaceutical leadership, including his current role as Organon’s Head of Research & Development and Chief Medical Officer. 〔0〕 That is directly relevant to EB613’s next hurdle: converting positive Phase 2 biomarker and bone-density data into a registrational program and eventual regulatory filing. 〔1〕 This is a capability upgrade, not a clinical or regulatory milestone. The filing does not announce new trial data, an FDA decision, a financing, or a change to the development timeline. It strengthens the board’s apparent fit for the company’s late-stage and women’s-health strategy, but any value is indirect and still has to show up through trial execution and regulatory progress. Bottom line: The board change modestly improves Entera’s development and regulatory bench as EB613 approaches Phase 3, but it does not materially de-risk the program today or change the company’s near-term milestones.**
EB613 Phase 3 study initiation, late 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!